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approved by the institutional review board, and written informed 
consent was obtained from each subject before the study.
Results: Plasma concentration of MNA, renal creatinine clearance, 
and CLTS,MNA were 9.9 (8.1) ng/mL, 139 mL/min/1.66 m2, and 
181 (110) mL/min/1.66 m2, respectively, indicating that the tubular 
secretion of MNA is involved in its renal clearance. Eight SNPs, 
–151C> A, –66T> C, 191G> A, 373C> T, 708C> T, 1490G> C, IVS5–
12G> C, and IVS5–4G> A, were detected on SLC47A1 gene with 
minor allele frequencies of 0.009, 0.194, 0.009, 0.009, 0.083, 0.009, 
0.343, and 0.463, respectively. A loss-of-function allele of SLC22A2, 
808G> T, was detected with minor allele frequency of 0.105 and 1 
subject was found having this variant as homozygote. She showed 
almost null CLTS,MNA; therefore, this subject was excluded from the 
analysis. Seventeen subjects having either –66C/C or T/C alleles 
showed a trend toward reduced CLTS,MNA compared with those hav-
ing the wild-type genotype (151 [IQR, 107–167] vs 184 [115–227] 
mL/min/1.66 m2; P = 0.08). Other variants showed no appreciable 
effects on CLTS,MNA.
Conclusion: We consider that CLTS,MNA may be a useful biomarker 
of the activity of renal organic cation transporters. The –66C allele 
of hMATE1/SLC47A1 may contribute to reduced renal clearance of 
MNA in healthy subjects not having homozygous 808G> T variant 
of hOCT2/SLC22A2.
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Introduction: More than 80 allelic variants have been described for 
CYP2D6 that result in poor (PM), efficient or extensive (EM) and 
ultrarapid (UM) metabolizers of CYP2D6 drug substrates. The dis-
tribution of PMs, Ems, and UMs varies markedly among human 
populations; however, it has been particularly difficult to determine in 
countries with wide ethnic diversity. Currently, the Mexican popula-
tion is composed of Mestizos (≈90%) and > 85 different ethno lin-
guistic indigenous populations (Mexican-Amerindians). Lacandones 
and Tzeltales are Mexican indigenous individuals that inhabit the 
state of Chiapas.
Aim: To perform a genetic analysis of CYP2D6 to determine the 
frequency of the hypothetical PM and UM status in Lacandones, 
Tzeltales, and 2 mestizo populations and compare it with previously 
reported Mexican populations.
Patients (or Materials) and Methods: The CYP2D6 genotype was 
analyzed in 154 Mexican Lacandones (ML), 26 Tzeltales (MT), 
249 Mexican Mestizos from Central Mexico (MM1), and 100 
Mexican Mestizos from Chiapas (MM2) healthy volunteers. All 
participants gave informed consent before its participation. The 
study was approved by the local ethical committee. Genomic DNA 
was extracted from blood samples by standard techniques. CYP2D6 
genotyping was performed by PCR for CYP2D6*5 and multiplica-
tion alleles, TaqMan® assays (AB) were used for CYP2D6*2,*3, *4, 
*6, *10, *17, *35, *41 and copy number variations. Differences in 
CYP2D6 allele frequencies were compared by using the chi-square 
(χ 2) test and/or Fisher’s exact test. Statistical analysis was done by 
STATISTICA 4.3 and GraphPad Prism 3.02 softwares.
Results: The PM frequency was very low in MM1 (0.8%) and 
MM2 (1%), while it was absent from MLs and MTs in a manner 
similar to 0% previously found in Tepehuanos and in other Mexican 
Amerindian populations. The UM phenotype frequency in MLs was 
also very similar to Tepehuanos (1.3% and 1.5%, respectively) and 
to Mexican American populations previously studied. In MTs the 
UM frequency was 0%, while MM1 and MM2 showed a 5.6% and 
3.0 frequency, respectively.
Conclusion: These data indicate that the frequencies of CYP2D6 PM 
and UM predicted phenotypes are very similar between Tepehuanos, 
Lacandones, and Tzeltales, but differ from Mexican Mestizos from 
Central and Southeastern Mexico. The predicted PM phenotype was 
very similar between MM from Central and Southeastern Mexico 
but varied in the frequency of UM. These findings reveal Mexican 
populations diversity that could have important implications in drug 
response to CYP2D6 substrates.
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Introduction: Epilepsy is the most prevalent chronic neurologic dis-
order that affects 65 million people worldwide. Phenytoin (PHT) is 
1 of the most widely prescribed antiepileptic drugs (AEDs); however, 
large interindividual variability in doses and concentrations has been 
observed in epilepsy treatment with PHT. Functional polymorphisms 
in genes encoding drug-metabolizing enzymes, drug transporters, 
and drug targets have been suggested to contribute to this genetic 
variability.
Aim: To evaluate the association of CYP2C9, CYP2C19, ABCB1, 
and ABCC2 polymorphism on PHT plasma levels in epileptic 
patients.
Patients (or Materials) and Methods: The present investigation was 
carried out in 57 consecutive patients (16–65 years) suffering epilepsy 
and treated with phenytoin. Approval from the institutional biomedi-
cal research ethics committee and the informed consent of patients 
was obtained before enrollment into the study. Genomic DNA was 
isolated from blood samples by standard technique. Genotyping 
of CYP2C9*2, CYP2C19*2 and *3, ABCB1 C1234T, C3435T, 
G2677A/T, ABCC2 G24A, and G1249A was performed by real-time 
